Compass Therapeutics, Inc.

NasdaqCM:CMPX Stock Report

Market Cap: US$335.0m

Compass Therapeutics Future Growth

Future criteria checks 5/6

Compass Therapeutics is forecast to grow earnings and revenue by 62.9% and 64.3% per annum respectively while EPS is expected to grow by 61.9% per annum.

Key information

62.9%

Earnings growth rate

61.88%

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth rate64.3%
Future return on equityn/a
Analyst coverage

Good

Last updated06 May 2026

Recent future growth updates

Recent updates

Seeking Alpha • Jan 20

Compass Therapeutics: Exciting Clinical Updates Inbound For 2026

Summary Compass Therapeutics remains a 'Buy,' but valuation above $1B stretches risk/reward as it awaits pivotal clinical catalysts. Tovecimig’s early data in biliary tract and refractory colorectal cancers show promise, with key COMPANION-002 updates expected late Q1 2026. CMPX’s cash runway extends into 2028, supporting continued clinical progress and mitigating near-term financing risk. Phase 1 data are preliminary; significant clinical and execution risks remain, and a better entry point may emerge if enthusiasm wanes. Read the full article on Seeking Alpha
Analysis Article • Sep 28

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jun 05

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 13

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 20

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Oct 11

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Compass Therapeutics (NASDAQ:CMPX) on Tuesday said it had entered into a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate its monoclonal antibody CTX-471 in combination with cancer drug Keytruda in a phase 1b study. As per the deal, CMPX will be the study sponsor while MRK will provide the clinical supply of Keytruda. The companies will form a joint development committee to review the clinical trial results, CMPX said in a statement. The combination arm of the early-stage trial will enroll patients with non-small cell lung cancer, melanoma, small cell lung cancer, mesothelioma, and head and neck cancer that have progressed after treatment with a PD-1 or PD-L1 inhibitor. CMPX stock +1.8% to $2.89 in premarket trading, while shares of MRK +0.2% to $90.65.

Earnings and Revenue Growth Forecasts

NasdaqCM:CMPX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028131-1820-3613
12/31/202727-85-73-7814
12/31/2026-1-80-77-6614
3/31/2026N/A-68-53-53N/A
12/31/2025N/A-66-49-49N/A
9/30/2025N/A-66-45-45N/A
6/30/2025N/A-62-45-45N/A
3/31/20251-55-44-44N/A
12/31/20241-49-45-45N/A
9/30/20241-48-48-48N/A
6/30/20241-47-43-43N/A
3/31/2024N/A-45-42-42N/A
12/31/2023N/A-42-41-41N/A
9/30/2023N/A-41-39-39N/A
6/30/2023N/A-43-44-44N/A
3/31/2023N/A-40-38-38N/A
12/31/2022N/A-39-34-34N/A
9/30/2022N/A-41-29-28N/A
6/30/2022N/A-35-22-21N/A
3/31/2022N/A-82-24-22N/A
12/31/2021N/A-82-22-20N/A
9/30/2021N/A-78-23-22N/A
6/30/2021N/A-81-26-25N/A
3/31/2021N/A-31-25-25N/A
12/31/2020N/A-29-27-27N/A
9/30/2020N/A-28-26-26N/A
6/30/2020N/A-27-26-25N/A
3/31/2020N/A-30-29-29N/A
12/31/2019N/A-35N/A-32N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CMPX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: CMPX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CMPX is expected to become profitable in the next 3 years.

Revenue vs Market: CMPX's revenue (64.3% per year) is forecast to grow faster than the US market (11.7% per year).

High Growth Revenue: CMPX's revenue (64.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CMPX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/17 07:51
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Compass Therapeutics, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Justin WalshB. Riley Securities, Inc.